S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
S&P 500   3,006.72 (+0.69%)
DOW   26,827.64 (+0.21%)
QQQ   193.39 (+0.89%)
Log in

Savara News Headlines (NASDAQ:SVRA)

$0.87
-0.01 (-1.14 %)
(As of 10/22/2019 09:30 AM ET)
Today's Range
$0.87
Now: $0.87
$0.87
50-Day Range
$0.84
MA: $1.91
$3.07
52-Week Range
$0.82
Now: $0.87
$11.96
Volume1,141 shs
Average Volume700,427 shs
Market Capitalization$35.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.2

Headlines

Savara (NASDAQ SVRA) News Headlines

Source:
DateHeadline
Zacks: Brokerages Expect Savara Inc (NASDAQ:SVRA) Will Post Earnings of -$0.44 Per ShareZacks: Brokerages Expect Savara Inc (NASDAQ:SVRA) Will Post Earnings of -$0.44 Per Share
www.americanbankingnews.com - October 21 at 1:16 PM
Have Insiders Been Buying Savara Inc. (NASDAQ:SVRA) Shares? - Yahoo FinanceHave Insiders Been Buying Savara Inc. (NASDAQ:SVRA) Shares? - Yahoo Finance
finance.yahoo.com - October 15 at 7:05 PM
Have Insiders Been Buying Savara Inc. (NASDAQ:SVRA) Shares?Have Insiders Been Buying Savara Inc. (NASDAQ:SVRA) Shares?
finance.yahoo.com - October 15 at 2:04 PM
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Hold" from BrokeragesSavara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 8 at 10:17 AM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA - Yahoo FinanceSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA - Yahoo Finance
finance.yahoo.com - October 7 at 11:06 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. - SVRA
finance.yahoo.com - October 7 at 11:06 PM
Company News For Oct 3, 2019 - Yahoo FinanceCompany News For Oct 3, 2019 - Yahoo Finance
finance.yahoo.com - October 3 at 8:49 PM
Thin ranks among premarket gainers - Seeking AlphaThin ranks among premarket gainers - Seeking Alpha
seekingalpha.com - October 3 at 8:49 PM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Savara Inc. (SVRA) - Yahoo FinanceBronstein, Gewirtz & Grossman, LLC Announces Investigation of Savara Inc. (SVRA) - Yahoo Finance
finance.yahoo.com - October 3 at 3:49 PM
Company News For Oct 3, 2019Company News For Oct 3, 2019
finance.yahoo.com - October 3 at 3:48 PM
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Savara Inc. (SVRA)Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Savara Inc. (SVRA)
finance.yahoo.com - October 3 at 3:48 PM
LADENBURG THALM/SH SH Reaffirms Hold Rating for Savara (NASDAQ:SVRA)LADENBURG THALM/SH SH Reaffirms Hold Rating for Savara (NASDAQ:SVRA)
www.americanbankingnews.com - October 3 at 3:39 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA - Yahoo FinanceSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA - Yahoo Finance
finance.yahoo.com - October 3 at 9:18 AM
31 Stocks Moving In Wednesdays Mid-Day Session - Benzinga31 Stocks Moving In Wednesday's Mid-Day Session - Benzinga
www.benzinga.com - October 3 at 4:18 AM
Mid-Day Market Update: United Natural Foods Falls On Downbeat Q4 Results; Immuron Shares Surge - BenzingaMid-Day Market Update: United Natural Foods Falls On Downbeat Q4 Results; Immuron Shares Surge - Benzinga
www.benzinga.com - October 2 at 9:43 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA
finance.yahoo.com - October 2 at 9:43 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRASHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA
www.benzinga.com - October 2 at 6:22 PM
Savara shares slide 48% premarket after FDA rejects lung-disease treatment MolgradexSavara shares slide 48% premarket after FDA rejects lung-disease treatment Molgradex
www.marketwatch.com - October 2 at 4:42 PM
Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development ProgramSavara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program
finance.yahoo.com - October 2 at 4:42 PM
Zacks: Brokerages Anticipate Savara Inc (NASDAQ:SVRA) to Announce -$0.43 Earnings Per ShareZacks: Brokerages Anticipate Savara Inc (NASDAQ:SVRA) to Announce -$0.43 Earnings Per Share
www.americanbankingnews.com - September 29 at 12:17 AM
Savara and AIM ImmunoTech among healthcare gainers; Clovis Oncology and Neogen among losers - Seeking AlphaSavara and AIM ImmunoTech among healthcare gainers; Clovis Oncology and Neogen among losers - Seeking Alpha
seekingalpha.com - September 24 at 4:04 PM
Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS - Yahoo FinanceSavara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS - Yahoo Finance
finance.yahoo.com - September 18 at 8:15 PM
Savara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERSSavara to Present Comprehensive Data From Pivotal Phase 3 IMPALA Study at 2019 ERS
finance.yahoo.com - September 18 at 8:15 PM
Edited Transcript of MSTX earnings conference call or presentation 8-Aug-19 8:30pm GMT - Yahoo FinanceEdited Transcript of MSTX earnings conference call or presentation 8-Aug-19 8:30pm GMT - Yahoo Finance
finance.yahoo.com - August 10 at 8:09 AM
Savara Inc. (SVRA) CEO Rob Neville on Q2 2019 Results - Earnings Call Transcript - Seeking AlphaSavara Inc. (SVRA) CEO Rob Neville on Q2 2019 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 9 at 8:26 AM
Savara Reports Second Quarter 2019 Financial Results and Provides Business Update - Business WireSavara Reports Second Quarter 2019 Financial Results and Provides Business Update - Business Wire
www.businesswire.com - August 9 at 8:26 AM
Savara Reports Second Quarter 2019 Financial Results and Provides Business UpdateSavara Reports Second Quarter 2019 Financial Results and Provides Business Update
finance.yahoo.com - August 9 at 8:26 AM
Savara to Report Second Quarter 2019 Financial Results and Provide Business Update - StreetInsider.comSavara to Report Second Quarter 2019 Financial Results and Provide Business Update - StreetInsider.com
www.streetinsider.com - August 3 at 7:43 AM
Savara to Present at the 39th Annual Canaccord Genuity Global Growth Conference - Yahoo FinanceSavara to Present at the 39th Annual Canaccord Genuity Global Growth Conference - Yahoo Finance
finance.yahoo.com - July 31 at 9:06 AM
Savara to Present at the 39th Annual Canaccord Genuity Global Growth ConferenceSavara to Present at the 39th Annual Canaccord Genuity Global Growth Conference
finance.yahoo.com - July 31 at 9:06 AM
Some Savara (NASDAQ:SVRA) Shareholders Have Taken A Painful 79% Share Price DropSome Savara (NASDAQ:SVRA) Shareholders Have Taken A Painful 79% Share Price Drop
finance.yahoo.com - July 15 at 7:07 PM
Hedge Funds Have Never Been More Bullish On Savara, Inc. (SVRA) - Yahoo FinanceHedge Funds Have Never Been More Bullish On Savara, Inc. (SVRA) - Yahoo Finance
finance.yahoo.com - June 26 at 8:21 AM
Hedge Funds Have Never Been More Bullish On Savara, Inc. (SVRA)Hedge Funds Have Never Been More Bullish On Savara, Inc. (SVRA)
finance.yahoo.com - June 26 at 8:20 AM
Savara to Present at the JMP Securities Life Sciences Conference - Business WireSavara to Present at the JMP Securities Life Sciences Conference - Business Wire
www.businesswire.com - June 15 at 8:02 AM
Why HEXO, Savara, and Cooper-Standard Holdings Slumped Today - The Motley FoolWhy HEXO, Savara, and Cooper-Standard Holdings Slumped Today - The Motley Fool
www.fool.com - June 13 at 7:43 PM
Savara to Present at the JMP Securities Life Sciences Conference - Yahoo FinanceSavara to Present at the JMP Securities Life Sciences Conference - Yahoo Finance
finance.yahoo.com - June 13 at 7:43 PM
Heres Why Savara Pharmaceuticals Collapsed Today - The Motley FoolHere's Why Savara Pharmaceuticals Collapsed Today - The Motley Fool
www.fool.com - June 13 at 7:43 PM
Savara Plunges After Lung Disease Drug Fails Phase 3 TrialSavara Plunges After Lung Disease Drug Fails Phase 3 Trial
finance.yahoo.com - June 13 at 7:43 PM
Savara to Present at the JMP Securities Life Sciences ConferenceSavara to Present at the JMP Securities Life Sciences Conference
finance.yahoo.com - June 13 at 7:43 PM
U.S. STOCKS ON THE MOVE-Beyond Meat, Twitter, Uber, Lyft, Energy companies - NasdaqU.S. STOCKS ON THE MOVE-Beyond Meat, Twitter, Uber, Lyft, Energy companies - Nasdaq
www.nasdaq.com - June 13 at 12:51 PM
U.S. STOCKS ON THE MOVE-RH, Lululeon, Tyson Foods, Beyond Meat - NasdaqU.S. STOCKS ON THE MOVE-RH, Lululeon, Tyson Foods, Beyond Meat - Nasdaq
www.nasdaq.com - June 13 at 12:51 PM
The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes - BenzingaThe Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes - Benzinga
www.benzinga.com - June 13 at 12:51 PM
Heres Why Savara Pharmaceuticals Collapsed Today - Yahoo FinanceHere's Why Savara Pharmaceuticals Collapsed Today - Yahoo Finance
finance.yahoo.com - June 13 at 12:51 PM
Savara Plunges on Failure of Late-Stage Study on Molgradex - Yahoo FinanceSavara Plunges on Failure of Late-Stage Study on Molgradex - Yahoo Finance
finance.yahoo.com - June 13 at 12:51 PM
Here's Why Savara Pharmaceuticals Collapsed TodayHere's Why Savara Pharmaceuticals Collapsed Today
finance.yahoo.com - June 13 at 12:51 PM
Savara Shares Slammed on Failed Phase 3 Drug Study - TheStreet.comSavara Shares Slammed on Failed Phase 3 Drug Study - TheStreet.com
www.thestreet.com - June 12 at 5:53 PM
Savara stock plummets 75% after drug study fails to hit target - MarketWatchSavara stock plummets 75% after drug study fails to hit target - MarketWatch
www.marketwatch.com - June 12 at 5:53 PM
Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)Savara Announces Results of IMPALA, a Phase 3 Study of Molgradex for the Treatment of Autoimmune Alveolar Pulmonary Proteinosis (aPAP)
finance.yahoo.com - June 12 at 5:53 PM
Savara stock plummets 75% after drug study fails to hit targetSavara stock plummets 75% after drug study fails to hit target
finance.yahoo.com - June 12 at 5:53 PM
Savara Shares Slammed on Failed Phase 3 Drug StudySavara Shares Slammed on Failed Phase 3 Drug Study
finance.yahoo.com - June 12 at 5:53 PM
This page was last updated on 10/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel